Cohort of Children With Acute Immune or Idiopathic Thrombocytopenic Purpura (ITP) : a Prospective Study in Pays De La Loire
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00331357|
Recruitment Status : Unknown
Verified May 2006 by University Hospital, Angers.
Recruitment status was: Not yet recruiting
First Posted : May 31, 2006
Last Update Posted : May 31, 2006
The objective of this study is to describe a paediatric population presenting an acute idiopathic thrombocytopenic purpura (ITP) and their evolution during their therapy in the region Pays de la Loire. The study will particularly evaluate the quality of life of these patients and their parents.
The secondary objectives are to identify the predictive factors of the complications, the repetitions and the chronicity of the ITP, to estimate the principal parameters of the economic cost of therapy of the children suffering from ITP according to the protocol of therapy, set up in the region Pays de la Loire and the constitution of a blood sample collection which allow a better understanding of the physiopathology of this disease.
It is about a prospective, multicentric clinical epidemiologic study of a paediatric cohort. Patients: 100 children from 0 to 17,99 years suffering from a first discovered ITP. The patients are not included if they present a serious, intercurrent, stabilized chronic pathology or not likely to modify the quality of life of the child and if they present a pathology other than the thrombopenia bringing into play the vital prognosis within a time lower than one year. These patients will be followed for 6 months according to the diagnosis of their ITP.
During the 6 months follow-up of each patient, the study will not carry out more consultations, nor more blood tests than the usual follow-up of a child suffering from ITP. On the other hand, in addition to the J0 questionnaire, it will be requested to the patient and to his family to fill in the questionnaires of quality of life and way of life during the consultations of J8, 1 month, 3 months and 6 months. A check-up of autoimmunity at 6 months will be carried out if the thrombopenia persists (this check-up is usual and not-specific to the study). At the time of the blood test for the control of the platelets at J0 and 6 months, an additional blood sample will be carried out: 5 ml are taken for the children of an age ≤ at 2 years, 10 ml from 2 to 4 years and 15 ml of blood for the children of an age > at 4 years. These blood samples are intended for the constitution of a blood sample collection.
The protocol of therapy of the children suffering from ITP is homogeneous in all centers, this protocol being a consensus established by the network of Oncopaediatrics of the Pays de la Loire. The instituted treatment will be in function of the gravity of the ITP expressed in 4 stages:
Stage I: Platelets > 20 gigas/L and absence of clinical signs. Stage II: Platelets > 10 gigas/L and hemorrhagic signs: haematomas, petechias or occasional epistaxis without repercussion on the daily life.
Stage III: moderate. Platelets > 10.000/mm3 and epistaxis with gauze pluggings or mucous lesions.
Stage IV: severe. Platelets ≤ 10.000/mm3 or fall of 2 grs/dl of haemoglobin with bleedings: epistaxis, melaena or haemorrhages requiring a blood transfusion or an hospitalization and important changes in the activities of the daily life.
Stages I and II do not receive any treatment and benefit from a simple monitoring.
Stages III benefit from either a corticosteroid treatment (Méthylprednisolone or Prednisone) at the dose of 4 mg/kg and per day in 2 intervals during 4 days (maximal dose of 100 mg/day) or a monitoring according to the appreciation of the clinician.
Stages IV profit in first intention from a treatment by Méthylprednisolone or Prednisone at the dose of 4 mg/kg and per day in 2 intervals during 4 days (maximal dose of 100 mg/jour).
The therapeutic attitude and the stadification belong to a regional consensus, established before the study, but each one can decide to apply a treatment according to the gravity of the clinical state of the child.
|Condition or disease|
|Acute Idiopathic Thrombocytopenic Purpura|
|Study Type :||Observational|
|Enrollment :||100 participants|
|Observational Model:||Defined Population|
|Observational Model:||Natural History|
|Official Title:||Cohort of Children With Acute Immune or Idiopathic Thrombocytopenic Purpura (ITP) : a Prospective Study in Pays De La Loire|
|Study Start Date :||June 2006|
|Study Completion Date :||December 2008|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00331357
|Contact: isabelle PELLIER, MD||IsPellier@chu-angers.fr|
|UH of Angers|
|Angers, France, 49933|
|Contact: Isabelle PELLIER, MD Ispellier@chu-angers.fr|
|Principal Investigator: Isabelle PELLIER, MD|
|Sub-Investigator: Xavier RIALLAND, MD|
|Sub-Investigator: Petronella RACHIERU, MD|
|Sub-Investigator: Estelle DARVIOT, MD|
|Hospital of Cholet|
|Cholet, France, 49 325|
|Contact: Guy SEGUIN, MD firstname.lastname@example.org|
|Principal Investigator: Guy SEGUIN, MD|
|Sub-Investigator: Francis CHOMIENNE, MD|
|Sub-Investigator: Sylvaine POIGNANT, MD|
|Sub-Investigator: Catherine RADET, MD|
|Sub-Investigator: Valérie COURTIN, MD|
|Sub-Investigator: Isabelle GRIMAL, MD|
|Hospital of La Roche Sur Yon|
|La Roche Sur Yon, France, 85 925|
|Contact: Nathalie GUILLEY, MD email@example.com|
|Principal Investigator: Nathalie GUILLEY, MD|
|Sub-Investigator: Dominique MEDINGER, MD|
|Hospital of Laval|
|Laval, France, 53 015|
|Contact: Joachim BASSIL, MD firstname.lastname@example.org|
|Principal Investigator: Joachim BASSIL, MD|
|Sub-Investigator: Eric PARIS, MD|
|Hospital of Le Mans|
|Le Mans, France, 72 037|
|Contact: Eliane TARRAL, MD email@example.com|
|Principal Investigator: Elaine TARRAL, MD|
|Sub-Investigator: Marie-Chantal CHEVALLIER, MD|
|UH of Nantes|
|Nantes, France, 44 093|
|Contact: Caroline THOMAS, MD firstname.lastname@example.org|
|Principal Investigator: caroline THOMAS, MD|
|Sub-Investigator: Françoise MECHINAUD, MD|
|Sub-Investigator: Nadège CORRADINI, MD|
|Hosptal of Saint Nazaire|
|Saint Nazaire, France, 44 606|
|Contact: Arnaud BOUTET, MD email@example.com|
|Principal Investigator: Arnaud BOUTET, MD|
|Study Director:||Isabelle PELLIER, MD||UH of Angers|